TRBV20-1 and lung carcinoma: Additionally, among the 9 VJ gene usages identified in lung cancer patients treated with Durvalumab, one of the identified V segments, TRBV20-1 has been previously shown to be differentially expressed in cancer tissue compared to healthy tissue (Wang et al., 2019).